HN2301 injection

DRUG3 trials

Sponsors

Shenzhen MagicRNA Biotechnology Co., Ltd

Conditions

Generalized Myasthenia GravisRefractory Myasthenia GravisRheumatoid ArthritisSclerodermaSystemic Lupus Erythematosus

Phase 1

Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）

RecruitingNCT06801119

Shenzhen MagicRNA Biotechnology Co., LtdRheumatoid Arthritis, Scleroderma, Systemic Lupus Erythematosus

Start: 2025-03-16End: 2028-06-30Target: 30Updated: 2026-08-12

Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)

Not yet recruitingNCT07556120

Shenzhen MagicRNA Biotechnology Co., LtdGeneralized Myasthenia Gravis

Start: 2026-12-31End: 2028-12-31Target: 6Updated: 2026-08-12

Unknown Phase

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

TerminatedNCT06965309

Shenzhen MagicRNA Biotechnology Co., LtdRefractory Myasthenia Gravis

Start: 2026-01-19End: 2026-02-11Updated: 2026-02-12